Table 3.

Mean changes ± SD at 36 months on clinical outcome measures of the ADNI CN population.

Enrichment strategy	ADAS11	ADAS12	CDR-SB	MMSE	RAVLT- total score	RAVLT- delayed recall
None	−0.47 ± 3.35	−0.17 ± 4.14	0.23 ± 0.82	−0.10 ± 1.38	−3.77 ± 8.91	−0.74 ± 3.49
ApoE ε4 carrier status	−0.06 ± 3.92	0.47 ± 4.86	0.32 ± 0.97	−0.27 ± 1.51	−5.45 ± 7.65	−1.45 ± 3.22
CSF Aβ	0.10 ± 3.89	0.56 ± 5.20	0.44 ± 1.14	−0.15 ± 1.15	−3.88 ± 8.08	−1.0 ± 3.38
CSF tTau	−0.08 ± 4.44	0.27 ± 5.93	0.50 ± 1.46	−0.22 ± 1.26	−3.83 ± 6.91	−0.61 ± 3.57
CSF pTau	0.04 ± 3.83	0.71 ± 5.10	0.32 ± 1.08	−0.21 ± 1.20	−5.21 ± 7.77	−1.03 ± 3.38
CSF ratio tTau/Aβ	−0.41 ± 3.65	0.14 ± 4.86	0.42 ± 1.17	−0.13 ± 1.10	−4.44 ± 7.80	−0.56 ± 3.46
CSF ratio pTau/Aβ	0.12 ± 3.50	0.83 ± 4.74	0.36 ± 1.01	−0.21 ± 1.23	−5.09 ± 7.55	−0.98 ± 3.23
FDG-PET	1.06 ± 7.64	1.39 ± 9.32	1.20 ± 2.44	−0.50 ± 1.78	−4.33 ± 13.38	−0.75 ± 3.33
Hippocampal volume	0.40 ± 3.73	1.02 ± 4.17	0.57 ± 1.18	−0.36 ± 1.58	−4.21 ± 11.15	−1.12 ± 4.13
Lateral ventricle volume	−0.23 ± 3.18	−0.18 ± 3.69	0.19 ± 0.50	−0.06 ± 1.64	−4.36 ± 10.48	−1.32 ± 2.68